Close Menu

NEW YORK (GenomeWeb News) – CardioDx today announced that national Medicare contractor Palmetto GBA will cover the company's Corus CAD gene expression test for coronary artery disease.

Since launching Corus CAD as a laboratory-developed test in 2009, the Palo Alto, Calif.-based cardiovascular genomics testing firm has been collecting clinical utility and cost data to expand insurance reimbursement of the test, which is used to determine which patients have or don't have CAD.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Dec
01
Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.